Joanne E. Murphy-Ullrich

Editorial

Joanne E. Murphy-Ullrich

us (code pays fourni par la source)

A latent TGF-β conjugated scaffold improves neocartilage development

Tianbai Wang, Yifan Peng, Bohao Huang, Enkhjargal Budbazar et autres

us (code pays fourni par la source)

A Bio-inspired Latent TGF-β Conjugated Scaffold Improves Neocartilage Development

Tianbai Wang, Bohao Huang, Enkhjargal Budbazar, Andrew Martin et autres

In cartilage tissue engineering, active TGF-β is conventionally supplemented in culture medium at highly supraphysiologic doses to accelerate neocartilage development. While this approach enhances cartilage extracellular matrix (ECM) biosynthesis, it further promotes tissue features detrimental to hyaline cartilage function, including the induction …

us (code pays fourni par la source)

Autoinduction-Based Quantification of In Situ TGF-β Activity in Native and Engineered Cartilage

Tianbai Wang, Sung Yeon Kim, Yifan Peng, Jane Zheng et autres

Transforming growth factor beta (TGF-β) is a potent growth factor that regulates the homeostasis of native cartilage and is administered as an anabolic supplement for engineered cartilage growth. The quantification of TGF-β activity in live tissues in situ remains a significant challenge, …

us (code pays fourni par la source)

Supplementary Methods from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy N. Trotter, Pramod S. Gowda et autres

Supplementary Methods Supplementary Methods descript detailed methods of Bioluminescence imaging, ELISA, Flow cytometry, Isolation and culture of Pre-OBs with 5TGM1-Luc MM cells, Generation and sorting of MDSCs, Cell proliferation assays, Treatment of MM cells with OB-Runx2+/+ and OB-Runx2-/- BMS in vitro, and …

Supplementary Table S1 from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy N. Trotter, Pramod S. Gowda et autres

Supplementary Table S1 Supplementary Table S1 shows the company's name and the product numbers of Bortezomib, 5-Fluorouracil and Gemcitabine as well as the company's name and the product numbers of all antibodies listed in table S1, which we purchased and used for …

Supplementary Figure S1-S6 from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy N. Trotter, Pramod S. Gowda et autres

Supplementary Figure S1-S6 Supplementary Figure S1 shows tumor burden in the mice before BTZ treatment started (S1A), MM cell growth and apoptosis after co-cultured with BMS or pre-OBs of OB-Runx2-/- or OB-Runx2+/+ mice (S1B-F), and the proportion of PMN-MDSCs and M-MDSCs in …

Supplementary Table S1 from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy N. Trotter, Pramod S. Gowda et autres

Supplementary Table S1 Supplementary Table S1 shows the company's name and the product numbers of Bortezomib, 5-Fluorouracil and Gemcitabine as well as the company's name and the product numbers of all antibodies listed in table S1, which we purchased and used for …

Data from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy N. Trotter, Pramod S. Gowda et autres

Abstract Multiple myeloma is a plasma cell malignancy that thrives in the bone marrow (BM). The proteasome inhibitor bortezomib is one of the most effective first-line chemotherapeutic drugs for multiple myeloma; however, 15% to 20% of high-risk patients do not respond to …

Data from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy N. Trotter, Pramod S. Gowda et autres

Abstract Multiple myeloma is a plasma cell malignancy that thrives in the bone marrow (BM). The proteasome inhibitor bortezomib is one of the most effective first-line chemotherapeutic drugs for multiple myeloma; however, 15% to 20% of high-risk patients do not respond to …

Supplementary Methods from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy N. Trotter, Pramod S. Gowda et autres

Supplementary Methods Supplementary Methods descript detailed methods of Bioluminescence imaging, ELISA, Flow cytometry, Isolation and culture of Pre-OBs with 5TGM1-Luc MM cells, Generation and sorting of MDSCs, Cell proliferation assays, Treatment of MM cells with OB-Runx2+/+ and OB-Runx2-/- BMS in vitro, and …

Supplementary Figure S1-S6 from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy N. Trotter, Pramod S. Gowda et autres

Supplementary Figure S1-S6 Supplementary Figure S1 shows tumor burden in the mice before BTZ treatment started (S1A), MM cell growth and apoptosis after co-cultured with BMS or pre-OBs of OB-Runx2-/- or OB-Runx2+/+ mice (S1B-F), and the proportion of PMN-MDSCs and M-MDSCs in …